Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hepatology
Main Authors: Bouattour, Mohamed, Raymond, Eric, Qin, Shukui, Cheng, Ann‐Lii, Stammberger, Uz, Locatelli, Giuseppe, Faivre, Sandrine
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Concise Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873445/
https://ncbi.nlm.nih.gov/pubmed/28862760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29496
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados